Springer Medicine

Hypertension is common in ICH, but inconsistent trial results have led to weak recommendations about acute blood pressure therapy. What target, timing, intensity, and agents should be used?

Polyvascular disease (atherosclerosis in multiple vascular beds) has a high prevalence and elevated risk of mortality. Early identification and treatment are crucial to reduce disease progression. 

Benefits of early intensive glycemic control in people with newly diagnosed type 2 diabetes persist up to 24 years after the UKPDS trial ended.

Adding tislelizumab to first-line chemotherapy significantly prolongs the overall survival of patients with advanced gastric or gastroesophageal junction cancer.

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

An expert-led symposium exploring the prevention and management of type 2 diabetes through dietary interventions. Highlights include discussion of the recent EASD guidelines, therapeutic diets, food types and processing, plus psychological factors that influence patient success, and the drivers of healthy eating and diabetes control.

An expert-led symposium exploring the most pertinent issues in cardio-oncology, with a focus on the new ESC guidelines. Highlights include preventative approaches in cardio-oncology, toxicity risk-stratification strategies, the clinical management of myocarditis as an adverse effect of immune checkpoint inhibitor-treatments, and the utility of biomarkers in long-term follow-up of cardiovascular disease risk in cancer patients.